CIK 0001410098
- Non-accelerated filer
CorMedix Inc.
Sign in to watch- Ticker
- CRMD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 908-517-9500
- Business address
- 389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
- Open-market buys, last 90 days
- $588,195
- in 4 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$588,195. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-02-28 | TELLEZ CORA M Director | Purchase | +1,540 | $2.10 | $3K | 118,071 |
| 2017-02-21 | TELLEZ CORA M Director | Grant or award · Stock Option (Right to Buy Common Stock) | +40,000 | 40,000 | ||
| 2017-02-21 | TELLEZ CORA M Director | Grant or award · Restricted Stock Units | +20,714 | 20,714 | ||
| 2017-02-21 | Markvicka Taunia Director | Grant or award · Stock Option (Right to Buy Common Stock) | +40,000 | 40,000 | ||
| 2017-02-21 | Markvicka Taunia Director | Grant or award · Restricted Stock Units | +13,571 | 13,571 | ||
| 2017-02-21 | Kaplan Myron Director | Grant or award · Stock Option (Right to Buy Common Stock) | +40,000 | 40,000 | ||
| 2017-02-21 | Kaplan Myron Director | Grant or award · Restricted Stock Units | +10,000 | 10,000 | ||
| 2017-02-21 | GEORGE MICHAEL W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +40,000 | 40,000 | ||
| 2017-02-21 | GEORGE MICHAEL W Director | Grant or award · Restricted Stock Units | +12,232 | 12,232 | ||
| 2017-02-21 | Dillione Janet Director | Grant or award · Stock Option (Right to Buy Common Stock) | +40,000 | 40,000 | ||
| 2017-02-21 | Dillione Janet Director | Grant or award · Restricted Stock Units | +15,357 | 15,357 | ||
| 2017-02-14 | GEORGE MICHAEL W Director | Purchase · Phantom Stock | +3,472 | $7,500.00 | $26.0M | 3,472 |
| 2017-02-14 | TELLEZ CORA M Director | Purchase · Phantom Stock | +3,472 | $7,500.00 | $26.0M | 3,472 |
| 2017-02-14 | Dillione Janet Director | Purchase · Phantom Stock | +3,472 | $7,500.00 | $26.0M | 3,472 |
| 2017-02-07 | Pfaffle Antony Chief Scientific Officer | Exercise or conversion | +10,000 | $0.68 | $7K | 10,000 |
| 2017-02-07 | Pfaffle Antony Chief Scientific Officer | Sale | −10,000 | $2.00 | $20K | 0 |
| 2017-02-07 | Pfaffle Antony Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | +10,000 | 70,000 | ||
| 2017-01-30 | Abrams Judith R Chief Medical Officer | Grant or award · Stock Option (Right to buy Common Stock) | +165,000 | 165,000 | ||
| 2017-01-30 | Abrams Judith R Chief Medical Officer | Grant or award · Stock Option (Right to buy Common Stock) | +185,000 | 185,000 | ||
| 2017-01-30 | Cook Robert W. Chief Financial Officer | Grant or award · Stock Option (Right to buy Common Stock) | +165,000 | 165,000 |
Page 22 of 24 · 463 trades